✦ LIBER ✦

Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection

✍ Scribed by Tomokazu Kawaoka; Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Yasuji Arase; Hitomi Sezaki; Yusuke Kawamura; Tetsuya Hosaka; Masahiro Kobayashi; Kenji Ikeda; Hiromitsu Kumada

Publisher: Springer Japan
Year: 2007
Tongue: English
Weight: 202 KB
Volume: 42
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-007-2015-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of adefovir add-on lamivudine r

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B

✍ Han Jak Ryu; Jung Min Lee; Sang Hoon Ahn; Do Young Kim; Myoung Ha Lee; Kwang-Hyu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## Abstract No study has reported on the comparative effect of adefovir (ADV) add‐on lamivudine (LAM) versus switching to entecavir (ETV) in LAM‐resistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAM‐resistant patients were enrolled (47 LAM + ADV and 45

Efficacy of lamivudine in HBeAg-negative

Efficacy of lamivudine in HBeAg-negative chronic hepatitis B

✍ Mario Rizzetto 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

## Abstract Hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg. It accounts for 7–30% of patients with chronic hepatitis B virus (HBV) worldwide, with the highest rates reported for Mediterranean Europe and Asia.

Serum cytokine levels in patients with c

Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy

✍ Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

## Abstract __Background__: Cytokines are known to play critical roles in the pathogenesis of chronic hepatitis B (CHB). However, the relationship between cytokines and treatment responses to drugs for CHB is not clearly defined yet. We measured the serum cytokine levels of interleukin (IL)‐1α, IL‐

Favorable efficacy of long-term lamivudi

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: An 8-year follow-up study

✍ Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Hitomi Sezaki; Tetsuya Hosaka; T 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

## Abstract The long‐term efficacy of lamivudine therapy in patients with hepatitis B virus (HBV) infection is still not clear. In this study, 20 non‐cirrhotic Japanese patients infected with HBV received lamivudine therapy for more than 1 year and were followed for a median period of 8.5 years (ra

Efficacy of entecavir in patients with c

Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone

✍ Ju Hyun Shim; Dong Jin Suh; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa C 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60